• Conference

    World Conference on Lung Cancer 2021

    NOVA is participating in the IASLC - WCLC World Conference on Lung Cancer which is being held from today until September 14th. Adèle L'Hostis will present two posters about NSCLC with our partner Janssen: "Multiscale NSCLC Tumor Growth Knowledge-Based Model Reproduces Tumor-Non-Progression under Gefitini", "Use of a Multiscale NSCLC Tumor Heterogeneity Model to Predict Tumor Growth Under Gefitinib". These posters are also available under our "Publications & posters" webpage.

    Read more
  • Hype cycle

    Novadiscovery (NOVA) is named as one of the "Trial Simulation" vendors in Gartner’s Hype Cycle for Life Science Research and Development, 2021

    According to Gartner, "Trials continue to get more expensive to run, and advanced technology, predictive analytics and simulation approaches can reduce enormous amounts of waste by ensuring the right trial is run. Synthetic arms can also optimize other trials, reducing the cost of starting up sites of low productivity." “Trial simulation technology can improve decision intelligence around protocol development, from drug interactions to site and subject locations, thereby avoiding unneeded trial work.” Click on "Read more" to access Gartner’s 2021 Hype Cycle for Life Science Research and Development, written by analysts Jeff Smith and Michael Shanler. Cutting-edge clinical trial simulation specialists such as NOVA are hard at work to ensure the technology reaches its full potential, in tandem with partners such as pharmaceutical companies, as well as with global regulators to ensure these innovative approaches are integrated into clinical regulatory decisions going forward.

    Read more
  • Article

    News on Artificial Intelligence in drug development

    Novadiscovery mentioned in the Emersion Insights report by Dr Ulrik Kristensen discussing the red-hot market for AI Drug Development. According to the research, startups including NOVA have already raised $2.1B in the first half of 2021, highlighting the huge potential impact that AI can offer to human health and pharmaceutical development.

    Read more
  • Team

    Novadiscovery appoints Grégoire Boutonnet as Chief Operating Officer

    With over 20 years of experience in innovation, product strategy, and digital entrepreneurship, Gregoire joins us at an exciting time as we continue to develop our #insilico platform, #JINKO and our library of Models.

    Read more
  • In silico

    Interview: Replace, Reduce, Refine: In-Silico Trials in The Spotlight

    Our CEO, François-Henri Boissel-Henri Boissel, recently spoke with Clinical OMICs, delving into the value of in silico trials in a post-pandemic environment, and highlighting their potential to bring down the overall cost of #clinicaltrials, as well as speed up drug development.

    Read more
  • Paper

    Position paper with the InSilicoWorld Community of Practice

    Novadiscovery took part in a position paper presenting the results of a consensus process in the InSilicoWorld Community of Practice, an online forum for experts in in silico medicine. This collective work identified 46 descriptions of possible CoUs. "Possible Contexts of Use for In Silico trials methodologies: a consensus- based review", M. Viceconti et al, IEEE Journal of Biomedical and Health Informatics, 2021

    Read more
  • Conference

    Novadiscovery at VivaTech on Sanofi's booth

    The Sanofi team is hosting a talk at 11.45 am today at the Viva Technology Conference and has invited Novadiscovery to join. So if you would like to learn more about NOVA and our clinical trial simulation platform, JINKO, come join us!

    Read more
  • NOVA

    What is NOVA ?

    The impact of the pandemic, our new partnership with Sanofi, Takeda and Janssen Inc., regulatory dossiers and what's next for NOVA... All answers are in this interview of our CEO François-Henri Boissel.

    Read more
  • Paper

    Building mechanistic model credibility

    While the value of in silico trials in drug development has been convincingly demonstrated, international standards for their evaluation are still a work in progress. We are delighted delighted to have participated, alongside other experts, in the publication of a paper which proposes a framework for building mechanistic model credibility."Scientific and regulatory evaluation of mechanistic in silico drug and disease models in drug development: building model credibility." Flora T. Musuamba et al., CPT Pharmacometrics Syst Pharmacol, 2021

    Read more
  • Partnership

    Takeda partners with NOVA

    NOVA has entered into a new collaboration with Takeda aimed at incorporating clinical trial simulation technology on virtual patients into Takeda France’s access strategy.

    Read more
  • In silico

    From Clinical Trial Efficacy to Real‑Life Effectiveness: Why Conventional Metrics do not Work

    Why is there a need to develop and validate functional and relevant translation approaches for the translation of clinical trial efficacy to the real-world setting.

    Read more
  • Financials

    NOVA raises Series A2 financing from Sanofi to advance JINKO, its best-in-class clinical trial simulation platform

    The funds will be used to advance NOVA’s in silico clinical trial simulation platform, JINKO; to faciliate the Company’s expansion into the US; and develop a COVID-19 disease model in collaboration with Sanofi.

    Read more
  • Partnership

    ElsaLys Biotech and Novadiscovery awarded €3.35 million by Bpifrance to advance inolimomab in graft-versus-host disease

    NOVA awarded €2.4 million to leverage Jinkō®, its best-in-class clinical trial simulation platform, to conduct in silico studies for graft-versus-host disease

    Read more
  • In silico

    Interview: L'approche in silico, vers des essais cliniques 100 % virtuels ?

    Novadiscovery's CEO Francois-Henri Boissel discusses the importance of in silico clinical trials in drug discovery and development with BiologisteInfo.

    Read more
  • In silico

    Nova cited in Gartner’s Life Science CIOs: May Your Pathway to Digital Trials

    Novadiscovery has been included in Gartner’s research titled ‘Life Science CIOs: Map Your Pathway to Digital Trials,’ written by analyst Jeff Smith.  According to the report, “There has been a great deal of hype around digital clinical trial approaches, with advocates noting the improved patient centricity, efficiency and recruitment. Life science CIOs must separate fact from fiction, and develop a well-crafted strategic roadmap to achieve their digital trial objectives.” Gartner believes that, “by 2021, 40% of the top 100 life science companies will begin to implement digital trial pilot programs.” Leading clinical trial simulation specialists such as Nova are working diligently to partner closely with researchers and pharmaceutical companies to ensure proper utilization of the technology, and also working with global regulators to ensure this innovation is incorporated into regulatory processes.

    Read more
  • Partnership

    We are pleased to announce our collaboration with Janssen France

    Novadiscovery announces key collaboration with Janssen France to provide in silico based decision support for clinical development.

    Read more
  • Competition

    Transatlantic leaders forum & Final of the startup tour 2020- FrenchFounders

    We are proud to be a part of the Startup Tour FrenchFounders’ finalists, with 6 other start-ups - out of 150 worldwide applications

    Read more
  • In silico

    We are pleased to note that the European Commission has referred to computer #modelling and #simulation in recent publications on building a European Health Union.

    in the Commission’s ‘Proposal to extend the mandate of the European Medicines Agency’, specifically aimed at boosting crisis preparedness, the proposal references the need for the #EMA to, where appropriate, make use of computational models and simulations for clinical trials.

    Read more
  • Conference

    Nova will attend the AI for Health Conference on November the 10th

    Organized by Startup Inside, this full day 100% digital worldwide summit gathers actors of the European Artificial Intelligence ecosystem operating in four countries to help Fortune 500 companies in their digital transformation.

    Read more
  • Conference

    Nova's poster presentation at the BioSB2020 conference

    At the BioSB2020 conference, Novadiscovery's biomodelers team presented a poster about how in silico clinical trials can demonstrate inhibition of reactive oxygen species production in ST elevated myocardial infarction.

    Read more
  • In silico

    Article: Prof. Boissel outlines the urgent need for disruptive R&D approaches that can tackle the search for COVID-19 treatments more effectively

    “There is an urgent need to turn to a disruptive approach, modeling and simulation, to make efforts to tackle COVID-19 more efficiently". Professor Jean-Pierre Boissel, Novadiscovery’s Co-Founder and Chair of the Scientific Advisory Board has written an article published today in pharmaphorum.

    Read more
  • NOVA

    Novadiscovery strengthens leadership team with senior appointments

    Experienced executives join Novadiscovery to support the next phase of growth and expansion into the US

    Read more
  • Conference

    Nova will attend the BioEurope Conference from Oct 26th to 29th

    BIO-Europe® Digital will be so much more than scheduled virtual partnering meetings, recorded content, some live sessions and virtual networking opportunities with panels on BD&L, Finance, Therapeutic Areas and up-to-the-minute Spotlight topics released weekly up until BIO-Europe officially opens

    Read more
  • Conference

    Nova will attend the BioPharm America Conference from Sept 21st to 24th

    BioPharm America will focus on innovation and investing, with the added collaboration of a number of diverse partners, whose unique offerings include live and recorded panel discussions, workshops and fireside chats from AI Applications for Drug Delivery and Development, LeadingBiotech Boston CEO&BD, Drug Delivery Partnerships, as well as a Startup Pitch Competition.

    Read more
  • Conference

    Nova will attend the 4D Meets AI Conference from Sept 17th to 18th

    4D Meets AI is a partnering conference organized by Life Science Nation (LSN) that connects investors and strategic partners and matches them to companies developing and commercializing AItechnology in drugs, devices, diagnostics, and digital health (the 4 Ds) to revolutionize healthcare.

    Read more
  • Conference

    Nova to present a poster in collaboration with Elsalys at VPH 2020

    Nova will present at VPH 2020 a poster on in silico disease model of onset, progression and treatment of steroid-refractory acute graft-versus-host disease (aGvHD)

    Read more
  • Regulatory

    The EMA has published today its Regulatory Science Strategy to 2025 in which Modeling & simulation plays a prime role

    In this strategy several key strategic goals will accelerate the uptake of in silico evidence in the regulatory context of drug - developmentFoster innovation in clinical trials - Optimise capabilities in modelling, simulation and extrapolation - Exploit digital technology and artificial intelligence in decision making

    Read more
  • Regulatory

    EMA publishes an article on regulatory science for in silico clinical trials co-authored by Nova and other key players of the industry

    Current status, gaps, and challenges in assessment of in silico models (including quantitative systems pharmacology models) for regulatory submissions.

    Read more
  • In Silico

    COVID-19 : It’s time to accelerate the adoption of clinical trials simulation by biotechs and pharmaceutical companies.

    Coronavirus pandemic forces some research labs to shut down, with uncertain outlook for scientific projects. As our CEO, François-Henri Boissel explained, the adoption of clinical trials simulation by biotechs and pharmaceutical companies is an opportunity to continue to move their R&D programs forward.

    Read more
  • Financials

    Novadiscovery a l’ambition de rendre la R&D des pharma plus efficace

    Le développement de médicaments n’intègre jusqu’ici que peu d’outils de simulation par ordinateur. Ces essais in silico sont pourtant essentiels pour mieux cibler les efforts.

    Read more
  • In Silico

    Startup of the Week - Novadiscovery Carries out Clinical Trials using AI and Simulations

    Novadiscovery, founded in 2010, aims to reduce the enormous cost of clinical trials by running the trials first in silico. The aim is to save costs by optimizing the design, dosage, timing, and patient selection prior to running the trial for real.

    Read more
  • Financials

    Novadiscovery raises series A financing to scale its in silico clinical trial platform – Debiopharm leads the round with EUR 5 million

    Novadiscovery has closed the first 5 million euros of a 7 million euros Series A funding round with Debiopharm. Novadiscovery will use the funding to scale its in silico clinical trial simulation platform Jinkō® in a software as a service (SaaS) model and develop further disease models, enabling its clients to directly conduct their in silico trials, and to develop its presence on the US market, the largest market globally for drug development.

    Read more
  • Conference

    Nova will be in San Francisco for the JP Morgan conference next January

    The annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.

    Read more
  • Regulatory

    A regulatory landscape for in silico clinical trials (p.18) [TOPRA]

    Modelling and simulation (M&S) has grown to become a reliable approach to better understand and optimise key decisions related to safety, efficacy, dosing, and special target populations. As both computing power and our understanding of human systems biology improve, the increased use of M&S motivates regulators to consider this new type of digital evidence to support medical device and medicinal drug product development and allow new approaches in clinical trials, in view of increasing the probability of success, reduce costs and accelerate time to patients

    Read more
  • In Silico

    La santé, cible ultime des doubles virtuels [LES ECHOS]

    La complexité de l'anatomie humaine fascine les informaticiens. En reproduisant son fonctionnement, ils ouvrent de nouvelles voies thérapeutiques.

    Read more
  • Poster

    Nova to present a poster in collaboration with Enyo Pharma at AASLD 2019

    Novadiscovery presented at the AASLD (American Association for the study of liver diseases) conference a poster explaining how they helped Enyo Pharma optimize the design of their phase II clinical trial, finding the best treatment combination for HBV infection.

    Read more
  • Conference

    Nova will be in Hamburg for BIO Europe from Nov 11th to 13th

    Come and meet Novadiscovery's team to learn more about in silico clinical trials and understand how virtual patients can help you derisk your drug decision making

    Read more
  • Award

    Nova is one the the 3 nominees of the Prix Galien

    Presented by the Galien Foundation and Business France, the Prix Galien – Medstartup encourages and rewards the most promising startups in healthcare formed through international partnerships between French, Israeli, and north American innovators. The program brings together innovators and stakeholders to facilitate rapid adoption and encourages the diffusion of new technologies to improve the state of human health.

    Read more
  • Regulatory

    Nova meets with the FDA to discuss validation of computational models

    Another interesting meeting with the FDA cardiovascular division to help the french biotech OP2 move its asset toward market approval faster with the support of insilico modeling & simulation. Thank you Voisin Consulting Life Sciences (VCLS) & IDDI for your continuous support !

    Read more
  • Conference

    Nova will attend the 19th Annual Biotech in Europe Forum in Basel from Sept 25th to 26th

    The 19th Annual Biotech in Europe Forum is recognised as the leading international stage for those interested in investing and partnering in the biotech and life science industry.

    Read more
  • Regulatory

    Nova meets with the EMA to discuss the future of in silico clinical trials

    Another productive meeting last week with OP2 team, Voisin Consulting Life Sciences (VCLS) & IDDI at the European Medicines Agency (EMA) discussing the future of in silico clinical trials

    Read more
  • In Silico

    Le double virtuel du patient, prochaine révolution de la santé [LES ECHOS]

    Plusieurs jeunes pousses sont dans les starting-blocks pour proposer des solutions dans ce domaine : tels Novadiscovery, qui élabore des modèles mathématiques pour réaliser des essais cliniques in silico, plus rapides et meilleur marché

    Read more
  • Regulatory

    Meeting #2 with the FDA for the MIDD pilot program

    Novadiscovery, along with partners OP2 and Voisin Consulting Life Sciences (VCLS), had another productive discussion at the FDA regarding the use of its in silico platform for clinical trials.

    Read more
  • Conference

    Nova at the Center for Innovation in Medicine in the context of Romanian Presidency at EU Council

    Meet our colleague Alexander Kulesza from Novadiscovery at the high-level Conference "The value of data in oncology" organized by the Center for Innovation in Medicine in the context of Romanian Presidency at EU Council. To fight cancer, there is a need for a true personalized approach for prevention, early detection, diagnosis and treatment. Insilico clinical trials are the way forward to address heterogeneity and complexity of the disease through modeling

    Read more
  • Conference

    Nova will be in Philadelphia for the BIO Convention from June 3rd to 7th

    The BIO International Convention is hosted by the Biotechnology Innovation Organization (BIO). BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.

    Read more
  • Conference

    Nova to present the Knowledge Management module of Jinkō to the scientific community of PLASCAN (Preventing tumor cells plasticity and adaptability).

    A online collaborative platform developed by Nova to organize and share scientific knowledge.

    Read more
  • Conference

    Nova to present its viewpoint on artificial intelligence and immunotherapies

    MabDesign and Lyonbiopole organized a day dedicated to the use of Artificial Intelligence to accelerate the development of Immunotherapies. This event gathered together nearly 80 stakeholders working in Artificial Intelligence applied to health, large groups developing immunotherapies that use these approaches, as well as academic laboratories, start-ups and biotechs that develop the latest innovations in the field. The event highlighted the place of Artificial Intelligence tools from the discovery phases of immunotherapy candidates (drug discovery, early stage, biomarker discovery, NGS), through bioproduction until their use during clinical trials (in silico trials, data management, diagnosis, personalized medicine).

    Read more
  • Regulatory

    Meeting #1 with the FDA for the MIDD pilot program

    Novadiscovery, along with partners OP2Drugs and VoisinConsulting, met with the FDA last week to share its expertise on in silico clinical trials as part of the Agency's Model-Informed Drug Development (MIDD) pilot program.

    Read more
  • Conference

    Nova will be in Vienna for BIO Europe from March 25th to 27th

    Come and meet Novadiscovery's team to learn more about in silico clinical trials and understand how virtual patients can help you derisk your drug decision making

    Read more
  • Conference

    Nova will be in San Francisco for the JP Morgan conference next January

    The annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.

    Read more

Julie

Is here to answer your questions or requests.

Do you have any questions for me?

If you want to join the team, please visit our careers section to see all vacancies available

Select a team please
First name is required
Last name is required
Job title is required
Company is required
Email is not valid
Message is required